Nonmetastatic castration-resistant prostate cancer (nmCRPC) represents a clinically significant stage of prostate cancer (PC) characterized by rising prostate-specific antigen (PSA) levels despite castrate levels of testosterone and no radiographic evidence of metastasis. The gene discussed is KLK3; the disease is pachyonychia congenita.